EUVIMEDEUVIMED entdecken
Crossref

Real world experience of using oral Systemic Anti Cancer Therapy (Abiraterone, Apalutamide and Enzalutamide) in advanced hormone-sensitive prostate cancer patients

Nity Singh, Taufik Hairudin, Govind Singh

Clinical Oncology · 2026-06 · 54 · 104109

DOI: 10.1016/j.clon.2026.104109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Oncology, 2026-06. Verfasst von Nity Singh und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Singh, N., Hairudin, T., & Singh, G. (2026). Real world experience of using oral Systemic Anti Cancer Therapy (Abiraterone, Apalutamide and Enzalutamide) in advanced hormone-sensitive prostate cancer patients. Clinical Oncology, 54, 104109. https://doi.org/10.1016/j.clon.2026.104109

Vancouver

Singh N, Hairudin T, Singh G. Real world experience of using oral Systemic Anti Cancer Therapy (Abiraterone, Apalutamide and Enzalutamide) in advanced hormone-sensitive prostate cancer patients. Clinical Oncology. 2026;54:104109. doi:10.1016/j.clon.2026.104109

BibTeX
@article{Singh2026,
  author = {Singh, Nity and Hairudin, Taufik and Singh, Govind},
  title = {Real world experience of using oral Systemic Anti Cancer Therapy (Abiraterone, Apalutamide and Enzalutamide) in advanced hormone-sensitive prostate cancer patients},
  journal = {Clinical Oncology},
  year = {2026},
  volume = {54},
  pages = {104109},
  doi = {10.1016/j.clon.2026.104109}
}
Kostenlos starten →